- Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating GlobeNewswire
- Facing backlash from scientific community, Cassava drops interim Alzheimer’s data with plenty of caveats FierceBiotech
- SAVA Stock Saga Continues; Shares Dive Despite Promising Alzheimer’s Test Investor’s Business Daily
- Cassava shares jump 21% on top-line data from simufilam Alzheimer’s disease trial Seeking Alpha
- SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today? InvestorPlace
- View Full coverage on Google News